Back

Effectiveness and safety of apixaban, dabigatran and warfarin compared to rivaroxaban in non-valvular atrial fibrillation; a Norwegian nationwide cohort study

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Prevention of thromboembolism and atrial remodelling in atrial fibrillation Treatment ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Ole-Christian Walter Rutherford

Sykehuset Ostfold Kalnes, Sarpsborg (Norway)

8 More presentations in this session

Presentation thumbnail
Equally high detection rates of atrial fibrillation in patients after a TIA and stroke by systematic ECG monitoring with an implanted device: SPIDER-AF study
Doctor F. Goss (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Non valvular atrial fibrillation, contraindication to anticoagulation or antiplatelet therapy and heart team approach: a single centre experience
Doctor A. Graffigna (Trento, IT)
Abstract Slides Video
Presentation thumbnail
Non-vitamin K antagonist oral anticoagulants are safe and effective alternatives to warfarin across subgroups by renal function: results from Danish registries
Doctor A. Nissen Bonde (Roskilde, DK)
Abstract
Presentation thumbnail
High mortality in atrial fibrillation patients suffering ischemic stroke, intracranial hemorrhage or a gastrointestinal bleed and associations with the preceding antithrombotic treatment
Professor P. Hjemdahl (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of non-vitamin K oral anticoagulants in patients with atrial fibrillation and cancer
Doctor I. Cavallari (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Prevention of thromboembolism and atrial remodelling in atrial fibrillation

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Interactive discussion and Q&A
thumbnail
Congress Session
Treatment strategies for atrial fibrillation in heart failure
thumbnail
Congress Session
EHRA Myths - Device-detected atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources